Kornimate/medical-research-clean huggingface dataset:
analysis of different hip adductors exercises

Conditions: Injury of Hip and Thigh

Summary: groin injuries present a major problem in sports due to its high frequency, long-lasting symptoms and high risk of re-injury. the most common groin injury is the adductor strain (around two thirds of all groin injuries), while the biggest risk factors are previous injury and lower hip adductors strength. the purpose of this study is to present and biomechanically evaluate several new strengthening exercises targeting hip adductors. exercises will be performed with the use of our novelty device, which enables eccentric strengthening of the hip adductors in different hip and knee positions. we hypothesize that performing modified hip adductors exercises using the novelty device could enable participants to perform hip adduction throughout larger rom during eccentric contractions, while changing hip and/or knee angle will differently affect muscle activity and produced joint torques. the latter could be helpful for preventive or rehabilitative training for hip adductors strain injuries, in which therapists want to target specific hip adductor muscle.

following the general warm-up (light aerobic activity, dynamic stretching exercises and bodyweight strength exercises), the electromyographic (emg) sensors and kinematic markers will be attached to the participant, who will then perform the maximal voluntary contractions for the purpose of emg normalization. then the participant will perform new hip adductor exercises using the novelty device, which enables hip adduction eccentric contractions in different hip and knee positions. the latter is important when trying to target specific hip adductor muscle, since different hip and/or knee angles differently affect individual muscle activity and joint torques. exercises will be performed in randomized order, while the emg and kinematic signals will be synchronously captured. emg muscle activity and joint torques, produced during the exercises, will be analysed. descriptive statistics will be calculated and reported as mean ± standard deviation. shapiro-wilk test will be used for testing of normality and levene's test for equality of variances. differences among corresponding variables will be obtained from different exercises and tested with the analysis of the variance for repeated measurements. for pair-wise comparisons, paired 2-tailed post-hoc t-tests with bonferroni's correction will be used. the level of statistical significance will be set at p \< 0.05.

Eligibility criteria:
inclusion criteria: performing regular physical activity, experience with strength training. exclusion criteria: neural, muscular, skeletal or connective tissue injuries during the last 12 months in the area of the back, hips and legs.

Keywords: sport injury prevention rehabilitation groin pain adductor strain
effectiveness and safety of early-stage amputation and external herbs chitosan for diabetic foot ulcer

Conditions: Diabetic Foot Ulcer

Summary: diabetic foot as the popular chronic complications of diabetes, is one of the main factors leading to limb amputation, it was reported that the amputation rate is 15 times of the non-diabetic patients. common surgical amputation is not only about high plane amputation but also bring a tremendous mental stress to patients which may affect the quality of life seriously. diabetic foot patients facing the great risk of serious infection, endotoxemia , and septic shock which could be the main cause of death before amputation. it become an important topic that how to control the infection, reduce the amputation plane, save the function as possibility, and improve the life quality of the patients as well. this study is based on years of clinical experience of and brings out "early-stage amputation" concept firstly in china with a systematic exposition, experimental research and clinical research. early-stage amputation refers to cut in the normal tissue from the inflammatory tissue at the junction line of limbs, in order to achieve more retained stump, block endotoxin absorption and improve the quality of life of patients. external therapy of herbs chitosan can promote granulation tissue regeneration and control of local infection, it solved the problem of difficult wound healing and it is a reliable guarantee of early-stage amputation.


Eligibility criteria:
inclusion criteria: 1. according to chinese herbs medicine standard for the diagnosis and treatment of diabetic foot, the individual diagnosed as diabetic foot with acromelic gangrene. 2. the individual aged between 18 and 70 years. 3. all wounds corresponded to wagner classification grade 4 or 5. 4. by appropriate treatment, skin temperature of limb with ulcer became warmer and it proved that the blood circulation recovery could be happening. 5. there were no obvious bruises or chromatosis in the necrosis skin. 6. persistent limb pain affected the sleep of the individuals. 7. the individual voluntarily signed the informed consent form. exclusion criteria: 1. acromelic gangrene caused by other reasons. 2. the individuals with server cardiovascular and cerebrovascular diseases or hepatic and kidney diseases do not adhere to surgery. 3. the individuals with the history of amputation. 4. the individuals with systemic inflammatory response syndrome, bacteremia, pyemia or shock. 5. vascular ultrasound shows artery is completely blocked. 6. the individuals do not adhere to the treatment or are with other treatments.

Keywords: diabetic foot ulcer early-stage amputation external therapy of herbs chitosan wound surface healing
an immunity persistence study of booster dose of live attenuated varicella vaccine

Conditions: Varicella

Summary: this an open-label phase ⅳ clinical trial of live attenuated varicella vaccine manufactured by sinovac (dalian) vaccine technology co., ltd.the purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 6 and 10 years after booster dose.

a total of 792 subjects aged 2 to 6 years including in per-protocol set (pps) of immunogenicity assessment from previous phase ⅲ clinical trial were enrolled. about 3.0ml of venous blood was collected at 6 and 10 years after booster immunization for antibody detection.

Eligibility criteria:
inclusion criteria: * subjects in pps of previous phase ⅲ clinical trial of varicella vaccine; * the subjects and/or guardian can understand and voluntarily sign the informed consent form; * proven legal identity. exclusion criteria: * beyond the blood collection window period; * history of varicella or shingles; * history of varicella vaccination since phase ⅲ clinical trial; * according to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
comparison of indigo naturalis oil extract and calcipotriol solution in treating psoriasis

Conditions: Nail Psoriasis

Summary: the purpose of this study is to compare the efficacy and safety of indigo naturalis oil extract and calcipotriol solution in the treatment of psoriatic nails, to show that indigo naturalis oil extract may be a good choice for treating nail psoriasis, and potentially an effective alternative for those who do not respond well to traditional therapy.

in the literature, the efficacy of traditional chinese medicine in treating nail psoriasis is rarely reported. recently, the investigators developed a new product, indigo naturalis oil extract, which worked well in nail disease. in our randomized, observer-blind, vehicle-controlled trial showed that indigo naturalis oil extract is effective and safe in treating nail psoriasis. this study aims to compare the efficacy and safety of indigo naturalis oil extract with calcipotriol solution in patients with nail psoriasis using controlled, bilateral comparison the investigators will enroll 33 patients with nail psoriasis from the ambulatory department of chang gung memorial hospital. indigo naturalis oil extract will be consistently applied on either the left or right affected nail folds, while calcipotriol will be applied on the opposite side, both twice daily for 24 weeks, allowing intra-patient comparison. the nails will be assessed by two dermatologists before treatment and at week 2, 4, 8, 12, 16, 20, 24.

Eligibility criteria:
inclusion criteria: 1. nail psoriasis of the matrix and/or of the nail bed in at least one fingernail. 2. good general health. 3. agreement to avoid pregnancy for the study duration exclusion criteria: 1. concomitant topical treatment (corticosteroids), phototherapy, or any systemic treatment (retinoids, cyclosporine, methotrexate, systemic corticosteroids and biological agents) that could affect nail psoriasis. 2. patients with severe hepatic or renal disorders. 3. lactating, pregnant or planning pregnancy 4. unwillingness to comply with study protocol. 5. a history of sensitivity to indigo naturalis. -

Keywords: nail psoriasis indigo naturalis indirubin calcipotriol nail psoriasis severity index
point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic clopidogrel bisulfate (plavitor®) with original clopidogrel bisulfate (plavix®)

Conditions: Acute Coronary Syndrome

Summary: this study demonstrates the effect of generic clopidogrel bisulfate (plavitor®) in comparison with the original clopidogrel bisulfate (plavix®) in patients with acute coronary syndrome.


Eligibility criteria:
inclusion criteria: 1. patients with unstable angina or non-st elevation myocardial infarction 2. patients who are planned coronary angiography 3. age \>18 years, \<75 years 4. patients who agree to the study protocol exclusion criteria: 1. recent treatment with clopidogrel or pletaal or glycoprotein iib/iiia rc antagonist 2. active bleeding (peptic ulcer, trauma or intra-cranial hemorrhage) 3. allergy to antiplatelet agent 4. bleeding diasthesis (blood coagulation disorders, uncontrolled severe hypertension, history of severe bleeding) 5. history of drug abuse or alcohol abuse 6. st elevation myocardial infarction 7. pregnancy 8. low platelet count (\< 100,000 /l) or abnormal results of pt or ptt 9. liver disease ( bilirubin \> 2 mg/dl, ast or alt \> 100 iu) 10. renal failure ( cr \> 2.0 mg/dl) 11. malignancy 12. proton pump inhibitor, nsaids statin (except atorvastatin)

Keywords: antiplatelet; clopidogrel; acute coronary syndrome
efficacy and tolerability of buscopan plus in painful gastric or intestinal spasms

Conditions: Gastrointestinal Diseases

Summary: study to evaluate efficacy and tolerability of buscopan® plus versus buscopan®, paracetamol, and placebo in patients with painful gastric or intestinal spasms.


Eligibility criteria:
inclusion criteria: * male and female patients * age: 18 - 70 years * diagnosis: recurring painful gastric or intestinal spasms such as occur e.g. in irritable bowel syndrome, which are not organic in origin, have been present for at least 2 months, and are serious enough to interfere with everyday activities * patient briefing as per §§ 40/41 of the arzneimittelgesetz (amg) and patient's declaration of informed consent in writing, in agreement with good clinical practice (gcp) and current legal requirements * a pain assessment of 3 cm or more on the visual analog scale on at least one of the 2 days immediately preceding the second visit exclusion criteria: * painful gastric or intestinal spasms of organic origin such as crohn's disease, ulcerative colitis, lactose intolerance * tumour pain/malignant growths * patients with other severe pain states of organic origin (e.g. biliary colic) * mechanical stenoses of the gastrointestinal tract, megacolon * urinary retention associated with mechanical stenoses of the urinary tract (e.g. in prostate adenoma) * narrow-angle glaucoma * tachyarrhythmia * myasthenia gravis * glucose 6-phosphate dehydrogenase deficiency (danger of haemolytic anaemia) * known hypersensitivity to n-butylscopolammonium bromide or paracetamol * severe liver impairment (e.g. through chronic alcohol abuse, hepatitis): * a) serum-glutamate-oxalacetat-transaminase/ aspartate aminotransferase (sgot) higher than four times the norm * b) bilirubin \> 3 mg/dl * c) quick's value \< 70% * meulengracht-gilbert syndrome (metabolic disturbance with episodes of jaundice) * severe kidney failure: creatinine \> 2 mg/dl * known depression or known mental illness, anxiety disturbance * concomitant intake of analgesics, nonsteroidal antiinflammatory drugs (nsaids) and/or spasmolytics, anticholinergics, nitrates * concomitant medication affecting gastrointestinal motility * regular (daily) use of laxatives * drugs that induce liver enzymes * concomitant administration of chloramphenicol * use of narcotics * antidepressant treatment or treatment with psychoactive drugs * pregnancy and lactation * alcohol abuse (more than 60 g alcohol/day) * frequent vomiting that might prevent adequate absorption of the active ingredient after the film-coated tablet is taken * patients who are unlikely to be able to keep the examination appointments or cannot reliably take the study medication regularly * simultaneous participation in another clinical study * patients who are not trained in the vas (pi) at visit 1
osteoporosis and fall prevention with multiple interventions in the metropolitan area

Conditions: Osteoporosis Fracture

Summary: objectives to determine the effects of 3 exercise interventions on sarcopenic indices among community-dwelling older adults with high osteoporotic fracture risks. material and method the current study enrolled subjects who screened high risk of fall, osteoporosis/fracture by standardized questionnaires or frax. subjects at the national taiwan university hospital bei-hu branch (ntuhbb) were randomized into integrated care group (icg, target n=50) and muscle training group (mtg, target n=50). subjects from lingko chang gung memorial hospital (lcgmh) were all assigned into x-box group (xbg, target n=30). all participants received a cd-rom and a one education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, and coping strategy and another hour of professional led exercise program. icg subjects received once weekly group exercise while mtg subjects received twice weekly machine-based resistence training on major muscle groups. xbg subjects rececived twice weekly exercise with x-box based programs. major outcomes were muscle mass (measured by bio-impedance analysis), grip strength, walking speed, and lower leg extension power at baseline and after 12-weeks of intervention.


Eligibility criteria:
inclusion criteria: 1. older than 50 years of age 2. high risk as defined from one of the following criteria: * score\>=1 on one minute osteoporosis risk questionnaire * 10 year predicted fracture risk \>=20% for major osteoporotic fracture or \>=3% for hip fracture from frax * fall\>=2 times in pass 1 year 3. having a bone mineral density test within one year period 4. having the capability to understand the study and complete the study interventions 5. willing to participate for the intervention and study follow ups exclusion criteria: 1. people younger than 50 years of age 2. could not communicate because of hearing, visual, or cognitive problems 3. unable to stand and walk unaided (walking aids are acceptable)

Keywords: osteoporosis fall fracture sarcopenia exercise
medication adherence and "true" resistance in patients with resistant hypertension

Conditions: Hypertensive Disease; Hypertension, Resistant to Conventional Therapy

Summary: the purpose of this study is to estimate the proportion of patients with "true" resistance among patients referred to the medical outpatient department of the charité - universitätsmedizin berlin with the diagnosis "resistant hypertension". moreover, data on medication adherence will be collected based on therapeutic drug monitoring and on the answers to validated questionnaires. finally, efficacy, safety and costs of renal sympathetic denervation will be compared to an intensified drug treatment in an exploratory way.


Eligibility criteria:
inclusion criteria: * female or male adult patients with arterial hypertension and admission diagnosis of "resistant hypertension" * informed consent * exclusion of secondary arterial hypertension * kidney function (estimated glomerular filtration rate \[egfr\] ≥ 45 ml/min/1.73 m2) exclusion criteria: * age \< 18 years * secondary arterial hypertension * type 1 diabetes mellitus * unstable coronary heart disease, myocardial infarction or stroke in the last 6 months * psychiatric diseases * significant carotid stenosis (\> 70%) * pregnancy * chronic kidney disease (egfr \< 45 ml/min/1.73 m2) * severe liver injury (elevation of transaminases more than twofold the upper limit of normal) * abuse of alcohol or illegal drugs
nac effect on hox genes expressions in rif

Conditions: Female Infertility

Summary: comparison of the group treated with nac-supplementation and placebo- administered groups showed elevations in hoxa cluster genes (all members) expression level in endometrium of women with rif.

despite significant developments in assistant reproductive technology (art) that have overcome many underlying causes of infertility, pregnancy success rates remain relatively low, mainly due to implantation failure. embryo quality and endometrial receptivity are two significant factors that believed to be the key points in implantation. since recent studies that showed high expression of some hoxa genes affects on successful implantation rate, thus we examined the expression of hoxa genes in nac supplementation during window of implantation (woi) in women with (rif). also the effect of nac on the improvement of implantation in rif patients was investigated. forty unfertile women with a diagnosis of rif, referred to royan institute were included in the study. the study was of the type a single center, double blinded, placebo controlled, randomized trial. expression of hoxa genes were assessed on the day of woi (using real time pcr) biopsies from endometrium. subjects randomly assigned to receive either nac (a) or placebo (b) with both effervescent tablets having similar color, size and appearance. the patients were randomly categorized in two groups (a/b) to receive nac 1200 mg/day or placebo, for at-least 6 weeks before starting ovarian stimulation. pipelled-based biopsy from endometrium was done on specific day (19-21) of their cycle. then patients were undergone ovarian stimulation (using nac) ended to ivf treatment. rna extraction and cdna synthesis were performed from endometrium samples and then we evaluated expressions levels by real-time pcr. then we analyzed our data by independent sample t-test and mann-whitney u test.

Eligibility criteria:
inclusion criteria: 1. age between 20 and 40 years old 2. at least two ivf failure 3. bmi in the normal range exclusion criteria: 1. irregular menstrual cycle 2. taking hormonal drugs except thyroid medication 3. abnormal karyotype or chromosomal disorders 4. coagulation problems.

Keywords: implantation recurrent implantation failure n-acetyl cysteine hoxa cluster genes window of implantation
covid-19 patients admitted to the icu

Conditions: Covid19

Summary: a retrospective analysis of the adult covid-19 patients admitted to the icu. a chart review will be conducted and multiple baseline characteristics, demographics, and treatments given will be recorded. variables collected will include age, gender, bmi, smoking status, past medical history, vital signs on admission, symptoms on admission, duration of symptoms, laboratory results on admission, treatment given. treatment options will include (steroids, plasma exchange, ivig, antibiotics, mode of respiratory support). primary outcomes will include; death, duration of icu stay, duration of mechanical ventilation, in-hospital complications. a regression model will be used to predict poor prognostic factors. inclusion criteria: patients with confirmed pcr results for covid-19 and require icu admission. exclusion criteria: those with negative results, pediatric patients and those not requiring icu admission.


Eligibility criteria:
inclusion criteria: * adults * positive pcr test for covid-19 * require admission to icu exclusion criteria: * pediatric patients\\ * any patient not requiring admission to icu
long-term study of atomoxetine in children with attention-deficit/hyperactivity disorder (ad/hd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the study is long-term extension study to evaluate long-term safety and efficacy of atomoxetine in japanese pediatric patients with attention-deficit/hyperactivity disorder (ad/hd).


Eligibility criteria:
inclusion criteria: * patients who met all of the disease diagnostic and study criteria at visit 2 of previous placebo-controlled study, completed the study * patients wish to enter into this study exclusion criteria: * patients whose families anticipate a move outside the geographic range of the investigative site, or who plan extended travel inconsistent with the recommended visit interval
patient reported symptom control with thc or cbd use

Conditions: Cancer-Associated Pain; Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm

Summary: this study compares patients' attitudes regarding marijuana products for medical use and other treatments for cancer-related pain. this study may help researchers gain better understanding of patient's perception on their use of marijuana products in treating cancer-related pain and other common cancer-related symptoms.

primary objective: i. to determine the patient's reported preference for cancer pain improvement with opioids, opioids with delta-9-tetrahydrocannabinol (thc)-marijuana and/or opioids with cannabidiol (cbd). secondary objectives: i. to determine the association between perception of cancer-related symptom relief and use of thc-marijuana and/or cbd. ii. to compare patient perception of thc-marijuana and/or cbd versus (vs.) cancer treatments in treatment of cancer. iii. to evaluate patient report of adverse effects experienced while using thc-marijuana and/or cbd. iv. to evaluate patient reported concerns while using thc-marijuana and/or cbd. v. to evaluate patient attitude of dosing, forms and use of thc-marijuana and/or cbd. vi. to evaluate demographic, physical and psychosocial factors that influence patient perception and attitudes of thc-marijuana and/or cbd. vii. to explore the difference of patient perception of thc-marijuana and cbd in cancer centers in a legalized vs. a non-legalized state. viii. to explore the patient reported preference of thc-marijuana and cbd for cancer pain and symptom relief of patients in a supportive care center vs. integrative medicine center at university of texas (u.t.) md anderson. outline: patients' medical records are reviewed and then complete questionnaires over 27 minutes.

Eligibility criteria:
inclusion criteria: * patients (inpatient or outpatient) seen by the palliative care and integrative medicine teams at the university of texas md anderson cancer center (texas) and the palliative care team at banner md anderson cancer center (arizona) * patients must be primary residents of texas or arizona * patients able to speak and read english * patients are 18 years old and above * patients should have a cancer diagnosis, cancer-associated pain, and taking strong opioids (morphine, oxycodone, hydrocodone, hydromorphone, oxymorphone, methadone, fentanyl) * patients who have used in the past 3 months or are using alternative botanical pain management while under prescription opioids exclusion criteria: * patients who are not able to speak or read english * altered mental status as determined by the interviewer based on the ability to understand the nature of the study and consent process * patients who have not used medical marijuana and/or cbd products * patients who do not have cancer * patients who do not have cancer-associated pain * patients who are not taking opioids